Do Not Initiate HRT in a 65-Year-Old Woman with Uncontrolled Hypertension
Hormone replacement therapy should not be initiated in this patient—uncontrolled hypertension at age 65 represents a clear contraindication, and the cardiovascular risks substantially outweigh any potential benefits.
Primary Guideline Recommendations
The 2013 ESH/ESC guidelines explicitly state that HRT should not be used for primary or secondary prevention of cardiovascular disease 1. More specifically, these guidelines note that "it is not recommended that OCs be used in women with uncontrolled hypertension" 1, and while this refers to oral contraceptives, the principle extends to HRT given the similar cardiovascular concerns.
The U.S. Preventive Services Task Force (2003) concluded that the harms of estrogen-progestin therapy are likely to outweigh the chronic disease prevention benefits for most women 2. They specifically noted increased risks of CHD events, strokes, and pulmonary emboli.
Age-Specific Concerns
Age 65 is particularly problematic for HRT initiation. The most recent and highest-quality evidence comes from a 2026 retrospective cohort study of 83,147 women that found:
- Initiation of HRT at age 65 or older was associated with dramatically increased hazards:
- Any cancer: HR 2.216 (95% CI: 1.833-2.677)
- Cerebrovascular accident: HR 2.695 (95% CI: 2.358-3.079) 3
This study explicitly concluded that "initiation of HRT after age 65 is linked to significantly increased risks of cancer and vascular events, supporting current guidelines discouraging late initiation" 3.
The "Window of Opportunity" Concept
Guidelines emphasize the importance of timing—HRT may have some cardiovascular benefits when started within 10 years of menopause in younger perimenopausal women 4. However, this patient is well beyond that window, making the risk-benefit ratio decidedly unfavorable.
Blood Pressure Considerations
While some evidence suggests transdermal estradiol may have neutral or even beneficial effects on blood pressure in women with controlled hypertension 5, 6, 7, the key issue here is that the hypertension is uncontrolled.
The 2020 ISH guidelines prioritize achieving blood pressure control (target <130/80 mmHg, individualized for elderly based on frailty) 8. Adding HRT before achieving blood pressure control introduces unnecessary cardiovascular risk.
A 2024 meta-analysis demonstrated that oral conjugated equine estrogens plus progestogen actually increased systolic blood pressure (SMD = 0.60 mm Hg) and increased the risk of incident hypertension 9.
Clinical Algorithm
Step 1: Focus on optimizing blood pressure control first
- Follow ISH 2020 stepwise approach with ACEI/ARB, CCB, and thiazide-like diuretics 8
- Target BP <140/90 mmHg minimum (individualized for frailty in elderly) 8
- Achieve control within 3 months 8
Step 2: If severe menopausal symptoms require treatment:
- Consider non-hormonal alternatives (SSRIs, gabapentin, clonidine)
- If symptoms are truly debilitating and non-hormonal options fail, this would require:
- First achieving blood pressure control
- Comprehensive cardiovascular risk assessment
- Recognition that at age 65, the patient is outside guideline-recommended parameters
Step 3: If HRT were ever considered (which it should not be in this scenario):
- Only transdermal estradiol would be acceptable (never oral) 1, 4, 5
- Requires close blood pressure monitoring
- Use lowest effective dose for shortest duration
Common Pitfalls to Avoid
Do not confuse HRT for menopausal symptoms with HRT for chronic disease prevention—guidelines are clear that HRT should not be used for cardiovascular or osteoporosis prevention 1, 2
Do not assume "natural" or bioidentical hormones are safer—the cardiovascular risks apply regardless of formulation
Do not initiate HRT while blood pressure remains uncontrolled—this compounds cardiovascular risk
Do not overlook the patient's age—65 years is specifically identified as high-risk for HRT initiation 3
Bottom Line
The priority is achieving blood pressure control through evidence-based antihypertensive therapy 8. HRT initiation at age 65 with uncontrolled hypertension contradicts multiple guideline recommendations and recent high-quality evidence showing increased cardiovascular and cancer risks 1, 2, 3. The American Heart Association explicitly states that HRT should not be initiated for secondary prevention of CVD 10, and uncontrolled hypertension places this patient at high cardiovascular risk.